| Title |
Chondroitin sulphate: a focus on osteoarthritis
|
|---|---|
| Published in |
Glycoconjugate Journal, May 2016
|
| DOI | 10.1007/s10719-016-9665-3 |
| Pubmed ID | |
| Authors |
Mamta Bishnoi, Ankit Jain, Pooja Hurkat, Sanjay K. Jain |
| Abstract |
Chondroitin sulfate (CS) being a natural glycosaminoglycan is found in the cartilage and extracellular matrix. It shows clinical benefits in symptomatic osteoarthritis (OA) of the finger, knee, hip joints, low back, facial joints and other diseases due to its anti-inflammatory activity. It also helps in OA by providing resistance to compression, maintaining the structural integrity, homeostasis, slows breakdown and reduces pain in sore muscles. It is most often used in combination with glucosamine to treat OA. CS is a key role player in the regulation of cell development, cell adhesion, proliferation, and differentiation. Its commercial applications have been continuously explored in the engineering of biological tissues and its combination with other biopolymers to formulate scaffolds which promote and accelerate the regeneration of damaged structure. It is approved in the USA as a dietary supplement for OA, while it is used as a symptomatic slow-acting drug (SYSADOA) in Europe and some other countries. Any significant side effects or overdoses of CS have not been reported in clinical trials suggesting its long-term safety. This review highlights the potential of CS, either alone or in combination with other drugs, to attract the scientists engaged in OA treatment and management across the world. |
Mendeley readers
The data shown below were compiled from readership statistics for 202 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| Unknown | 201 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 29 | 14% |
| Student > Bachelor | 29 | 14% |
| Student > Master | 26 | 13% |
| Researcher | 19 | 9% |
| Other | 12 | 6% |
| Other | 26 | 13% |
| Unknown | 61 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 38 | 19% |
| Biochemistry, Genetics and Molecular Biology | 21 | 10% |
| Agricultural and Biological Sciences | 13 | 6% |
| Chemistry | 10 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 4% |
| Other | 40 | 20% |
| Unknown | 71 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2017.
All research outputs
#22,759,452
of 25,374,647 outputs
Outputs from Glycoconjugate Journal
#870
of 929 outputs
Outputs of similar age
#305,492
of 349,583 outputs
Outputs of similar age from Glycoconjugate Journal
#22
of 29 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 929 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,583 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.